Valbiotis Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hyperc

TOTUM•070 demonstrates excellent results in volunteers with blood LDL cholesterol levels above 130 mg/dl at randomization, its commercially targeted population and the primary subpopulation of the HEART study:Increased and lasting efficacy on blood LDL cholesterol levels, with a reduction of 13.7% after three months...

Related Keywords

Germany ,United States ,Paris ,France General ,France ,Quebec ,Canada ,Riom ,Auvergne ,French ,American , ,European Regional Development Fund ,University Hospital Of Nantes ,Research Development ,Young Innovative Company ,Industrial Affairs ,Public Affairs ,European Union ,American Heart Association Annual Meeting ,Innovative Company ,American Heart Association Annual ,Regulatory News ,University Hospital ,Institut De Canc ,American Heart Association ,Valbiotis Board ,Commercial Operations ,Quebec City ,Valbiotis Universal Registration Document ,French Financial Markets Regulator ,Public Affairs Director ,